148 related articles for article (PubMed ID: 24357797)
1. IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation.
Smith E; Ruszkiewicz AR; Jamieson GG; Drew PA
Br J Cancer; 2014 Feb; 110(3):775-82. PubMed ID: 24357797
[TBL] [Abstract][Full Text] [Related]
2. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation.
Chen Y; Cui T; Knösel T; Yang L; Zöller K; Petersen I
Lung Cancer; 2011 Jul; 73(1):38-44. PubMed ID: 21095038
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
4. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.
Peng DF; Razvi M; Chen H; Washington K; Roessner A; Schneider-Stock R; El-Rifai W
Gut; 2009 Jan; 58(1):5-15. PubMed ID: 18664505
[TBL] [Abstract][Full Text] [Related]
5. Progressive silencing of p14ARF in oesophageal adenocarcinoma.
Huang Y; Peters CJ; Fitzgerald RC; Gjerset RA
J Cell Mol Med; 2009 Feb; 13(2):398-409. PubMed ID: 18410530
[TBL] [Abstract][Full Text] [Related]
6. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
[TBL] [Abstract][Full Text] [Related]
7. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
[TBL] [Abstract][Full Text] [Related]
8. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
9. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
10. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
[TBL] [Abstract][Full Text] [Related]
11. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas.
Soldes OS; Kuick RD; Thompson IA; Hughes SJ; Orringer MB; Iannettoni MD; Hanash SM; Beer DG
Br J Cancer; 1999 Feb; 79(3-4):595-603. PubMed ID: 10027336
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
14. IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk.
Di Martino E; Wild CP; Rotimi O; Darnton JS; Olliver RJ; Hardie LJ
Biomarkers; 2006; 11(6):547-61. PubMed ID: 17056474
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.
Wijnhoven BP; Hussey DJ; Watson DI; Tsykin A; Smith CM; Michael MZ;
Br J Surg; 2010 Jun; 97(6):853-61. PubMed ID: 20301167
[TBL] [Abstract][Full Text] [Related]
16. Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.
Barclay JY; Morris A; Nwokolo CU
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):221-7. PubMed ID: 15674101
[TBL] [Abstract][Full Text] [Related]
17. Association of insulin-like growth factor binding protein-7 promoter methylation with esophageal cancer in peripheral blood.
Kaya Z; Almalı N; Sahin ES; Duran S; Görgisen G; Ates C
Mol Biol Rep; 2022 May; 49(5):3423-3431. PubMed ID: 35076852
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Downregulation and Growth Inhibition of IGFBP7 in Gastric Cancer.
Kim J; Kim WH; Byeon SJ; Lee BL; Kim MA
Asian Pac J Cancer Prev; 2018 Mar; 19(3):667-675. PubMed ID: 29580038
[TBL] [Abstract][Full Text] [Related]
19. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
20. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]